title: Continuous administration of heparin in patients with deep vein thrombosis can increase plasma levels of diamine oxidase.
abstract: Besides its anticoagulant activity, the sulfated polysaccharide heparin has numerous other biological effects. Especially the antiinflammatory and immunoregulatory properties of heparin may be associated with its ability to release the histamine-degrading enzyme diamine oxidase (DAO) from tissue-bound sites into the circulation. Whereas DAO activity is at the limits of detection in normal human plasma, the application of heparin leads to a significant increase of plasma DAO activity. However, previously, only the effect of bolus injection of unfractionated heparin (UFH) had been studied. To investigate DAO release during continuous heparin infusion, 28 patients with deep vein thrombosis (DVT) undergoing heparin therapy were analyzed. Whereas continuous heparin infusion did not lead to any increase of plasma DAO activity in 12 patients (43%), 6 patients (21%) showed a single elevated and 10 patients (36%) permanently elevated plasma DAO activity. The groups of patients exhibiting different DAO release responses did not differ in age, sex, body weight, concomitant diseases, heparin infusion rates, coagulation indices, location and extension of thrombosis, or clinical outcome. However, the rate of idiopathic DVT was significantly higher in the group of patients releasing DAO. This study shows, for the first time, that continuous heparin infusion can lead to DAO release and that individuals exhibit considerable differences in their release response. Although the significance of heparin-induced DAO release needs further clarification, our results indicate that postheparin plasma DAO activity could be an interesting parameter correlated with idiopathic DVT.
authors.affiliation: Klinische Abteilung für Gefässchirurgie, Universitätsklinik für Chirurgie, Universität Innsbruck, Austria.
authors.forename: Josef
authors.initials: J
authors.lastname: Klocker
authors.forename: Reinhold
authors.initials: R
authors.lastname: Perkmann
authors.forename: Peter
authors.initials: P
authors.lastname: Klein-Weigel
authors.forename: Gabriele
authors.initials: G
authors.lastname: Mörsdorf
authors.forename: Astrid
authors.initials: A
authors.lastname: Drasche
authors.forename: Anton
authors.initials: A
authors.lastname: Klingler
authors.forename: Gustav
authors.initials: G
authors.lastname: Fraedrich
authors.forename: Hubert G
authors.initials: HG
authors.lastname: Schwelberger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006631:Amine Oxidase (Copper-Containing) / Q000097:blood*; D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006493:Heparin / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000201:enzymology
chemical_list: D000925:Anticoagulants; D006493:Heparin; D006631:Amine Oxidase (Copper-Containing)